类风湿关节炎合并糖尿病的心血管风险管理:一项国际审计
RA-DM组ASCVD患病率26.7%,高于RAwoDM组的11.6%(p<0.001);多数ASCVD患者未达到LDL-C<1.8 mmol/L目标,但RA-DM组血脂达标率在有无ASCVD者中均显著高于RAwoDM组;收缩压<140 mmHg达标率两组无显著差异。
要点
- RA合并糖尿病患者ASCVD患病率26.7%,显著高于无糖尿病RA患者的11.6%。
- 多数ASCVD患者未达到LDL-C<1.8 mmol/L目标,但RA-DM组血脂达标率高于RAwoDM组。
- 收缩压<140 mmHg达标率两组无统计学和临床显著差异。
核心结论
- RA合并糖尿病患者的CVD预防用药使用率和ASCVD患病率均高于无糖尿病的RA患者,且血脂目标达标率也更高。
- 可从糖尿病的心血管预防项目中借鉴经验以使RA患者临床获益。
研究设计与样本
- 队列来源于2014-2019年53个中心/19个国家/3大洲的类风湿关节炎患者心血管疾病危险因素调查。
- 研究比较RA-DM与RAwoDM的CVD患病率,并分为有和无ASCVD亚组比较危险因素和CVD预防治疗。
主要发现
- RA-DM组ASCVD患病率为26.7%,RAwoDM组为11.6%(p<0.001)。
- RA-DM组高血压、高脂血症诊断比例及降脂药或降压药使用比例均高于RAwoDM组(p<0.001)。
- 多数ASCVD患者未达到LDL-C<1.8 mmol/L的血脂目标。
- RA-DM组血脂达标率在有无ASCVD患者中均统计学和临床显著高于RAwoDM组。
- 收缩压<140 mmHg目标多数患者达到,RA-DM与RAwoDM组间达标率无统计学和临床显著差异。
关键数值与推荐
- 血脂目标为低密度脂蛋白胆固醇<1.8 mmol/L(LDL-C<1.8 mmol/L)。
- 收缩压目标为<140 mmHg。
临床怎么用
- 对RA合并糖尿病患者应关注ASCVD高患病率并加强心血管风险管理。
- 多数ASCVD患者LDL-C未达标,提示需强化降脂治疗。
- RA-DM患者血脂达标率高于RAwoDM,可借鉴糖尿病心血管预防项目经验用于RA患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: The objective was to examine the prevalence of atherosclerotic cardiovascular disease (ASCVD) and its risk factors among patients with RA with diabetes mellitus (RA-DM) and patients with RA without diabetes mellitus (RAwoDM), and to evaluate lipid and blood pressure (BP) goal attainment in RA-DM and RAwoDM in primary and secondary prevention. METHODS: The cohort was derived from the Survey of Cardiovascular Disease Risk Factors in Patients with Rheumatoid Arthritis from 53 centres/19 countries/3 continents during 2014-2019. We evaluated the prevalence of cardiovascular disease (CVD) among RA-DM and RAwoDM. The study population was divided into those with and without ASCVD, and within these groups we compared risk factors and CVD preventive treatment between RA-DM and RAwoDM. RESULTS: The study population comprised of 10 543 patients with RA, of whom 1381 (13%) had DM. ASCVD was present in 26.7% in RA-DM compared with 11.6% RAwoDM (p<0.001). The proportion of patients with a diagnosis of hypertension, hyperlipidaemia and use of lipid-lowering or antihypertensive agents was higher among RA-DM than RAwoDM (p<0.001 for all). The majority of patients with ASCVD did not reach the lipid goal of low-density lipoprotein cholesterol <1.8 mmol/L. The lipid goal attainment was statistically and clinically significantly higher in RA-DM compared with RAwoDM both for patients with and without ASCVD. The systolic BP target of <140 mm Hg was reached by the majority of patients, and there were no statistically nor clinically significant differences in attainment of BP targets between RA-DM and RAwoDM. CONCLUSION: CVD preventive medication use and prevalence of ASCVD were higher in RA-DM than in RAwoDM, and lipid goals were also more frequently obtained in RA-DM. Lessons may be learnt from CVD prevention programmes in DM to clinically benefit patients with RA .
引用
- Semb AG, Rollefstad S, Ikdahl E, et al. Diabetes mellitus and cardiovascular risk management in patients with rheumatoid arthritis: an international audit. RMD Open. 2021. PMID: 34244381. doi:10.1136/rmdopen-2021-001724
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。